CD80/CD86 Blockade and T-Cell Dynamics

How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?

Abatacept reduces CD4+ T-cell activation by blocking CD28 costimulation and shifts cells toward naive phenotypes, but achieves reversible immunosuppression rather than permanent tolerance, with paradoxical effects on regulatory T cells varying by disease context.

Abstract

CD80/CD86 blockade by abatacept consistently reduces T-cell activation across multiple disease contexts through selective modulation of CD28-mediated costimulation. Treatment decreases expression of activation markers (CD38, ICOS, Ki-67) and reduces proliferation particularly in CD4+ T cells, with 7-10-fold fewer proliferating and activated effector memory CD4+ T cells observed in GVHD prevention. Abatacept shifts CD4+ compartments toward naive phenotypes while reducing central memory populations, with transcriptional analysis revealing decreased expression of genes regulating cell cycle and chromatin dynamics. CD8+ T-cell subsets remain relatively resistant to these effects, indicating lesser reliance on CD28 costimulation. The effects are reversible after treatment discontinuation, with T-cell populations returning to baseline within 6 months, indicating that abatacept maintains an altered immune state through continuous pharmacological inhibition rather than inducing permanent tolerance.

Effects on regulatory T cells are context-dependent and paradoxical: in rheumatoid arthritis, abatacept increases Treg numbers through reduced apoptosis but diminishes their suppressive function because CD80/CD86 blockade on responder T cells reduces susceptibility to Treg-mediated suppression, while in multiple sclerosis, memory Treg frequencies decrease due to their dependence on ongoing costimulation. Clinical translation of these immunological effects varies substantially by disease, with robust benefits observed in GVHD prevention where transient early suppression of donor T-cell activation is sufficient, sustained benefits in established rheumatoid arthritis with high baseline T-cell activation, but no clinical improvement in mild atopic asthma despite similar shifts in T-cell populations. This heterogeneity suggests that costimulation blockade is most effective when CD28-dependent T-cell responses drive disease pathology and baseline immune activation is high.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?” The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

• Abatacept Intervention: Does this study investigate abatacept as the primary intervention?
• T-cell Outcomes: Does this study measure T-cell activation markers (e.g., CD25, CD69, cytokine production, proliferation assays) or T-cell tolerance outcomes (e.g., regulatory T-cell function, anergy markers, immune suppression indicators)?
• Control Groups: Does this study include appropriate comparison groups (placebo, standard care, or pre-treatment baseline)?
• Study Design: Is this study a randomized controlled trial, controlled clinical trial, or systematic review/meta-analysis?
• Intervention Isolation: Can the effects of abatacept be isolated from other interventions in this study?
• Study Setting: Is this a human or animal study with in vivo or clinical correlation (not purely in vitro)?
• Publication Status: Is this a peer-reviewed, published study with complete methodological details (not a conference abstract or unpublished study)?
• Intervention Specificity: Does this study focus on abatacept rather than other CD80/CD86 blocking agents without abatacept?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper.

• Study Model: Disease type/condition studied, study population characteristics relevant to T-cell function, experimental approach (in vivo, ex vivo, clinical trial), control groups used for comparison.
• Abatacept Regimen: Dose and dosing schedule, duration of treatment, route of administration, timing relative to outcome measurements, any concomitant immunosuppressive treatments.
• T-cell Activation Measures: Specific activation markers measured, proliferation assays or markers, functional activation measures, quantitative changes in activation levels, T-cell populations showing activation changes.
• T-cell Tolerance Measures: Regulatory T-cell frequency, phenotype, and function, suppressive function assays, anergy or hyporesponsiveness measures, tolerance-related cytokines, markers of peripheral tolerance or immune regulation, quantitative changes in tolerance mechanisms.
• T-cell Subset Effects: Naive vs. memory T-cell subset changes, effector vs. central memory populations, CD4+ vs. CD8+ T-cell differential effects, specialized subsets, quantitative changes in subset frequencies or absolute numbers, functional changes within specific subsets.
• Mechanistic Insights: Molecular and pathway-level insights into how CD80/CD86 blockade affects T-cell activation and tolerance, transcriptional changes, cell cycle and proliferation pathway effects, costimulation pathway modulation, chromatin dynamics, signal transduction pathway effects, metabolic changes in T-cells.
• Effect Kinetics: Temporal pattern of T-cell activation and tolerance changes, onset of effects, peak effect timepoints, duration and persistence of effects, reversibility after treatment discontinuation, differences in kinetics between activation and tolerance measures.
• Study Limitations: Factors that could affect interpretation of T-cell activation and tolerance effects from CD80/CD86 blockade, sample size limitations, confounding medications or treatments, technical limitations, patient population factors, missing timepoints, potential off-target effects.

Results

Characteristics of Included Studies

The included studies examined abatacept’s effects across diverse autoimmune and transplant contexts. Five studies had full text available. Disease models included rheumatoid arthritis (4 studies), type 1 diabetes (2 studies), GVHD prevention (2 studies), multiple sclerosis (1 study), and asthma (1 study). Most studies used approximately 10 mg/kg dosing at 4-week intervals, though treatment durations varied from 3 months to 24 months. Concomitant immunosuppression was common, including methotrexate in rheumatoid arthritis studies and calcineurin inhibitors plus methotrexate in GVHD prevention studies.

Effects on T-cell Activation

Activation Marker Expression

Abatacept treatment reduced expression of multiple T-cell activation markers across disease contexts. In GVHD prevention, CD4+ T cells showed 7-fold fewer proliferating cells (Ki-67+) and 10-fold fewer activated cells (CD38+/HLA-DR+) at day +28 compared to controls, with effects concentrated in effector memory populations. In multiple sclerosis, abatacept decreased the proportion of CD38+ and ICOS+ activated cells within both T follicular helper (Tfh) and regulatory T cell populations. Rheumatoid arthritis patients exhibited downregulation of activation-associated markers and CD95 on CD4+ T cells and Tregs.

The activation changes were selective for certain T-cell populations. CD4+ T cells were consistently more affected than CD8+ T cells across studies. In type 1 diabetes, CD4+ conventional and regulatory subsets showed altered frequencies while CD8+ subsets remained relatively resistant, indicating lesser reliance on CD28-mediated costimulation in CD8+ cells. This differential sensitivity extended to specialized subsets, with Tfh cells showing progressive frequency declines and reduced activation marker expression in multiple sclerosis patients.

Proliferation and Cell Cycle Effects

Transcriptional analysis revealed that abatacept disrupted cell cycle and proliferation pathways in activated T cells. In multiple sclerosis patients, abatacept reduced expression of genes regulating cell cycle and chromatin dynamics during cell proliferation, directly linking reduced costimulatory signaling to impaired activation and proliferation. This was consistent with functional proliferation measures showing significant inhibition of CD4+ T cell proliferation in GVHD prevention, affecting both effector and central memory subsets.

Inflammatory Biomarkers

Beyond cellular activation markers, abatacept reduced soluble inflammatory mediators associated with T-cell activation. In rheumatoid arthritis, 12 months of treatment significantly decreased serum levels of IL-6, soluble IL-2 receptor, C-reactive protein, soluble E-selectin, and soluble ICAM-1 compared to placebo. Smaller reductions in TNF-α and rheumatoid factor were also observed. These systemic changes reflected the anti-inflammatory and immunomodulatory effects of selective CD28 costimulation blockade.

Effects on T-cell Subset Distribution

Abatacept consistently shifted CD4+ T-cell compartments toward naive phenotypes while reducing memory populations. In type 1 diabetes, abatacept treatment significantly reduced central memory CD4+ T cells (CD45RO+CD62L+) while increasing naive CD4+ T cells (CD45RO-CD62L+). Similarly, asthma patients showed increased naive and decreased memory CD4+ T cells after 3 months.

Within memory populations, effects were selective. Multiple sclerosis patients showed specific decreases in CD45RO+ memory Tregs while CD45RA+ naive Tregs remained unaffected. Tfh cells, a specialized memory subset, decreased progressively in frequency with accompanying reductions in activated (CD38+/ICOS+) Tfh cells.

Effects on Regulatory T Cells and Tolerance

Abatacept’s effects on regulatory T cells varied by subset and assay. In rheumatoid arthritis, total Treg numbers increased after treatment initiation, but functional suppression assays revealed diminished capacity to suppress responder T-cell proliferation. This occurred because CD80/CD86 blockade on responder T cells reduced their susceptibility to Treg-mediated suppression.

Multiple sclerosis patients exhibited decreased Treg frequency, particularly affecting memory Tregs expressing CD38 and ICOS activation markers. The demethylation status of the TSDR region in the FOXP3 gene also decreased, suggesting reduction in bona fide stable Tregs. In GVHD prevention, CD4+CD25high/CD127low/FoxP3+ putative Tregs transiently decreased in the abatacept cohort early after transplantation compared to standard treatment.

Temporal Dynamics of Effects

The onset and kinetics of T-cell effects varied by subset. In GVHD prevention, significant inhibition of CD4+ T-cell proliferation and activation was evident by day +28, but similar levels of activation were observed in treated and control cohorts after day +100, indicating transient effects. The terminal half-life of abatacept (approximately 19.5 days) influenced the duration of immunological effects.

Type 1 diabetes studies demonstrated sustained effects during continuous treatment. Significant changes in central memory and naive CD4+ T cells were observed at 6, 12, and 24 months, persisting throughout the treatment period but returning to baseline values 6 months after treatment discontinuation. This reversibility was consistent across disease contexts, with multiple sclerosis patients showing complete reversal of cellular and molecular changes upon abatacept cessation.

Notably, different T-cell subsets exhibited distinct kinetic patterns.

Mechanistic Insights into Activation vs. Tolerance

Abatacept’s mechanism extends beyond simple CD80/CD86 blockade to affect multiple cellular processes. Transcriptional profiling in multiple sclerosis revealed that abatacept decreased expression of genes regulating cell cycle and chromatin dynamics during proliferation, linking reduced costimulatory signaling to impaired activation and cell division. The differential impact on CD4+ versus CD8+ T cells reflects their relative dependence on CD28 costimulation. CD8+ T-cell subsets showed resistance to abatacept effects in type 1 diabetes, suggesting lesser reliance on the CD28 pathway for activation and maintenance. This mechanistic distinction has important implications for which immune responses are modulated by costimulation blockade.

Rheumatoid arthritis studies revealed an additional mechanism: abatacept reduced CD95-mediated T-cell apoptosis, leading to increased T-cell numbers including Tregs. However, blockade of CD80/CD86 on responder T cells simultaneously diminished their susceptibility to Treg-mediated suppression, creating a paradox where Treg numbers increased but functional suppression decreased. This finding illustrates how costimulation signals serve dual roles in both effector T-cell activation and tolerance mechanisms.

Study Quality and Limitations

Several factors affect interpretation of these findings across studies. Sample size limitations were notable, particularly for immunological endpoints. Technical considerations included high variance in absolute T-cell subset counts and missing timepoints.

Conclusion

The evidence reveals a consistent pattern: abatacept reduces T-cell activation markers and shifts CD4+ compartments toward naive phenotypes while showing limited effects on CD8+ cells. However, the relationship between these immunological changes and clinical outcomes varies substantially across diseases, warranting careful examination of why similar T-cell effects produce different therapeutic results.